Supplementary Materials

Efficient Suppression of Abdominal Aortic Aneurysm Expansion in Rats by Systemic Administration of Statin-Loaded Nanomedicine

Natsumi Fukuhara 1, Yuto Honda 2,3, Nao Ukita 3, Makoto Matsui 2, Yutaka Miura 2,3,* and Katsuyuki Hoshina 1,*

1 Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan ; FUKUHARAN-SUR@h.u-tokyo.ac.jp (N.F.), traruba@gmail.com (K.H.)
2 Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan ; honda.y.ai@m.titech.ac.jp (Y.H.), matsu.m.ad@m.titech.ac.jp (M.M), miura.y.ai@m.titech.ac.jp (Y.M.)
3 Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; ukita.n.aa@m.titech.ac.jp (N.U.)
* Correspondence: miura.y.ai@m.titech.ac.jp (Y.M.), traruba@gmail.com (K.H); Tel.: +81-45-924-5225 (Y.M.), +81-35-800-8653 (K.H)

Supplementary Figures

Figure S1. GPC chart of PEG-P[Lys]45. Column: SuperdexTM 200 Increase 10/300 GL, eluent: 10mM phosphate buffer (pH7.4) containing 500 mM NaCl, flow rate: 0.5 mL/min, temperature: room temperature, detection: absorbance at 220 nm.
Figure S2. $^1$H-NMR spectrum of PEG-P[Lys(TFA)]$_{45}$ (solvent: DMSO).

Figure S3. $^1$H-NMR spectrum of PEG-P[Lys(TFA)]$_{45}$ (solvent: DMSO).
Figure S4. $^1$H-NMR spectrum of PEG-P[LYS(FPBA)]$_{45}$ (solvent: D$_2$O with 90 mg/mL of D-sorbitol).

Figure S5. Photomicrographs of organs after PS/m treatment. Hematoxylin and eosin-stained heart, liver, spleen, kidney, and muscles. Scale bars represent 50 $\mu$m in x20 images and 100 $\mu$m in x40 image.